Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LavipharmATH:LAVI -1.38%82 Equity-to-Asset is 0.43 as of Dec. 2025. GuruFocus rates ATH:LAVI with a GF Score™ of 82/100 and a GF Value™ of €1.24 (Modestly Overvalued). The stock has 9 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Lavipharm ranks worse than 71.73% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Lavipharm's Total Stockholders Equity for the quarter that ended in Dec. 2025 was €56.42 Mil. Lavipharm's Total Assets for the quarter that ended in Dec. 2025 was €130.22 Mil.
Therefore, Lavipharm's Equity to Asset Ratio for the quarter that ended in Dec. 2025 was 0.43.
The historical rank and industry rank for Lavipharm's Equity-to-Asset or its related term are showing as below:
ATH:LAVI'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.47 Med: -0.19 Max: 0.43
Current: 0.43
During the past 9 years, the highest Equity to Asset Ratio of Lavipharm was 0.43. The lowest was -0.47. And the median was -0.19.
ATH:LAVI's Equity-to-Asset is ranked worse than 71.73% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 0.6
vs ATH:LAVI: 0.43
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Lavipharm Equity-to-Asset Related Terms
Lavipharm Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Lavipharm's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ATH:LAVI vs ZTS, UTHR, VTRS: Equity-to-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Lavipharm's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lavipharm Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lavipharm's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Lavipharm's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Lavipharm's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lavipharm (ATH:LAVI) has a Equity-to-Asset of 0.43 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Lavipharm and its competitors. According to the industry distribution chart, Lavipharm ranks #723 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 71.7%.
Is Lavipharm's Equity-to-Asset too high?
Lavipharm's current Equity-to-Asset is 0.43. The Drug Manufacturers industry median Equity-to-Asset is 0.60. Lavipharm's value of 0.43 is 28.3% below this industry median. Based on the distribution chart, Lavipharm ranks #723 out of 1008 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Lavipharm has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lavipharm's Equity-to-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Lavipharm ranks #723 out of 1008 companies for Equity-to-Asset. This places Lavipharm in the lower half of its industry. The industry median Equity-to-Asset is 0.60. Lavipharm's value of 0.43 is 28.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.60, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lavipharm's current Equity-to-Asset of 0.43 is 28.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Lavipharm and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lavipharm's current Equity-to-Asset is 0.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lavipharm stock overvalued right now?
Based on GuruFocus' analysis, Lavipharm (ATH:LAVI) is currently considered Modestly Overvalued. The stock's GF Value™ is €1.24, compared to a current price of €1.57 — trading 26.5% above its estimated fair value. The current Equity-to-Asset is 0.43 and 28.3% below the Drug Manufacturers industry median of 0.60. Lavipharm's overall GF Score™ is 82/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Lavipharm (ATH:LAVI), the current Equity-to-Asset is 0.43 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lavipharm (ATH:LAVI) Overvalued in 2026?
Based on GuruFocus' analysis, Lavipharm stock appears to be overvalued.
The current stock price of €1.57 is trading 26.5% above its estimated GF Value™ of €1.24.
GuruFocus considers Lavipharm to be Modestly Overvalued.
Key valuation signals for ATH:LAVI:
Equity-to-Asset: 0.43
GF Value™: €1.24 vs. price of €1.57 (26.5% above fair value)
Industry Position: 28.3% below the Drug Manufacturers median (#723 of 1008)
No single metric tells the full story. See the ATH:LAVI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lavipharm SA develops, manufactures, markets, and distributes pharmaceutical, cosmetic, and consumer health products in Greece and internationally. The company's product portfolio includes safe and effective therapeutic solutions that meet consumers' needs for health and well-being. Its main product categories are Cardiology, Oncology, Urology, Neurology, Psychiatry, Chronic Pain, General Medicine, Self-Treatment, and Dermocosmetic care.
82GF Score
Get the complete analysis for ATH:LAVI
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATH:LAVI has been successfully added to your 
